First-in-human evaluation of 6-bromo-7-[11C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06851-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Severin Mairinger und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: ATP-Binding Cassette, Sub-Family C Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Purpose
Multidrug resistance-associated protein 1 (MRP1) is a transport protein with a widespread tissue distribution, which has been implicated in the pathophysiology of Alzheimer’s and chronic respiratory disease. PET with 6-bromo-7-[ 11 C]methylpurine ([ 11 C]BMP) has been used to measure MRP1 function in rodents. In this study, [ 11 C]BMP was for the first time characterised in humans to assess the function of MRP1 and other MRP subtypes in different tissues.
Methods
Thirteen healthy volunteers (7 men, 6 women) underwent dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [ 11 C]BMP. Three subjects of each sex were scanned a second time to assess reproducibility. Volumes of interest were outlined for MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, kidneys, and liver). From the time-activity curves, the elimination rate constant ( k E , h − 1 ) was derived as a parameter for tissue MRP function and its test-retest variability (TRTV, %) was calculated. Radiation dosimetry was calculated using the Medical Internal Radiation Dose (MIRD) methodology.
Results
Mean k E and corresponding TRTV values were: cerebral cortex: 0.055 ± 0.010 h − 1 (− 4 ± 24%), cerebellum: 0.033 ± 0.009 h − 1 (1 ± 39%), choroid plexus: 0.292 ± 0.059 h − 1 (0.1 ± 16%), retina: 0.234 ± 0.045 h − 1 (30 ± 38%), lungs: 0.875 ± 0.095 h − 1 (− 3 ± 11%), myocardium: 0.641 ± 0.105 h − 1 (11 ± 25%), kidneys: 1.378 ± 0.266 h − 1 (14 ± 16%), and liver: 0.685 ± 0.072 h − 1 (7 ± 9%). Significant sex differences were found for k E in the cerebellum, lungs and kidneys. Effective dose was 4.67 ± 0.18 µSv/MBq for men and 4.55 ± 0.18 µSv/MBq for women.
Conclusion
LAFOV PET/CT with [ 11 C]BMP potentially allows for simultaneous assessment of MRP function in multiple human tissues. Mean TRTV of k E in different tissues was in an acceptable range, except for the retina. The radiation dosimetry of [ 11 C]BMP was in the typical range of 11 C-tracers. LAFOV PET/CT holds great potential to assess at a whole-body, multi-tissue level molecular targets relevant for drug disposition in humans.
Trial registration
EudraCT 2021-006348-29. Registered 15 December 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
- QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
- Translational Neurodegeneration Research and Neuropathology Lab, Department of Clinical Medicine (KlinMed), Medical Faculty, University of Oslo, Oslo, Norway.
- Section of Neuropathology Research, Department of Pathology, Clinics for Laboratory Medicine (KLM), Oslo University Hospital, Oslo, Norway.
- Institute of Nutritional Medicine (INUM) and Lübeck Institute of Dermatology (LIED), University of Lübeck and University Medical Center Schleswig-Holstein, Lübeck, Germany.
Förderung
- Medical University of Vienna
Zitieren
APA
Mairinger, S., Jackwerth, M., Chalampalakis, Z., Rausch, I., Weber, M., Wölfl-Duchek, M., Pracher, L., Nics, L., Pahnke, J., Langsteger, W., Hacker, M., Zeitlinger, M., & Langer, O. (2024). First-in-human evaluation of 6-bromo-7-[11C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06851-2
Vancouver
Mairinger S, Jackwerth M, Chalampalakis Z, Rausch I, Weber M, Wölfl-Duchek M, et al. First-in-human evaluation of 6-bromo-7-[11C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06851-2
BibTeX
@article{Mairinger2024,
author = {Mairinger, Severin and Jackwerth, Matthias and Chalampalakis, Zacharias and Rausch, Ivo and Weber, Maria and Wölfl-Duchek, Michael and Pracher, Lena and Nics, Lukas and Pahnke, Jens and Langsteger, Werner and Hacker, Marcus and Zeitlinger, Markus and Langer, Oliver},
title = {First-in-human evaluation of 6-bromo-7-[11C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06851-2}
}
EUVIMED